Moderna Inc (WBO:MRNA)
€ 40.79 -0.515 (-1.25%) Market Cap: 16.15 Bil Enterprise Value: 10.93 Bil PE Ratio: 0 PB Ratio: 1.37 GF Score: 61/100

Moderna Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript

Dec 09, 2020 / 01:00PM GMT
George Farmer
BMO Capital Markets Equity Research - Analyst

Hi. Good morning, everyone, and welcome to the second day of BMO's Growth and ESG Conference. My name is George Farmer. I'm senior biotechnology analyst in -- with BMO. And it is my pleasure today to have us -- have with us Lavina Talukdar, who's the Senior Vice President and Head of Investor Relations for Moderna.

Moderna is an extremely exciting company, certainly very high-profile in the news lately on the forefront of coronavirus research. Moderna, as everyone knows, has one of the leading vaccine candidates in development. We saw some very exciting Phase III results from the company released not too long ago. But Moderna is certainly much more than just its coronavirus vaccine candidate, and we hope to dig into a little bit of that as well. But I do want to dedicate most of our time here to talking about the latest in the corona vaccine research space.

Questions & Answers

George Farmer
BMO Capital Markets Equity Research - Analyst

Along those lines, maybe we could start off,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot